[{"from": "human", "value": "Describe this molecule. [C][C][Branch1][C][C][O][C][=Branch1][C][=O][C@H1][Branch1][Branch1][C][C][S][C][N][C][=Branch1][C][=O][C][=C][Branch2][Ring1][P][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][C@@H1][C][C@@H1][Branch1][Branch1][C][N][Ring1][Branch1][S][C][=Branch1][C][=O][C][=C][N][=C][C][=C][Ring1][=Branch1][C][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F]"}, {"from": "gpt", "value": "The molecule is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued."}]